Compare PROP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | TENX |
|---|---|---|
| Founded | 2001 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 71.1M |
| IPO Year | 2008 | 2001 |
| Metric | PROP | TENX |
|---|---|---|
| Price | $0.45 | $1.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $6.75 | ★ $29.67 |
| AVG Volume (30 Days) | 2.6M | ★ 9.8M |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.43 | $1.31 |
| 52 Week High | $2.55 | $19.40 |
| Indicator | PROP | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 23.75 |
| Support Level | N/A | $1.31 |
| Resistance Level | $0.86 | $2.43 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | -0.02 | 0.37 |
| Stochastic Oscillator | 6.41 | 35.12 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.